10x Genomics, Lausanne University Hospital Partner for Cancer Biomarker Research

Editor’s Take: This collaboration builds on 10x’s broader efforts to work with leading research institutions to generate the scientific evidence needed to advance future diagnostic applications of single cell and spatial technologies. Other recent collaborators include CareDx Inc. and the Chan Zuckerberg Initiative.

10x Genomics Inc., a life science technology leader, has entered a research collaboration with Lausanne University Hospital (CHUV), one of Switzerland’s leading academic medical centers, to advance research in diagnostic applications of single cell and spatial technologies for cancer care.

Through this multi-year collaboration, the study intends to use 10x’s Flex Apex and Xenium platforms, with the goal of expanding to the Atera platform, to examine tumor samples from patients with advanced cancer undergoing a comprehensive evaluation by a clinical molecular tumor board. The research aims to identify clinically relevant biomarkers that may help predict treatment response, cancer prognosis and support diagnostic development.

“This collaboration brings together complementary expertise in spatial biology, pathology, computational AI and clinical precision oncology to address one of the biggest challenges in cancer care: predicting which patients will benefit from treatment,” said Raphael Gottardo, Professor and Director of the Biomedical Data Science Center, CHUV. “Together, we aim to discover clinically actionable biomarkers that improve patient selection and bring more precise treatment decisions closer to routine clinical care.”

The study is expected to include hundreds of patients across multiple solid tumor types, including non-small cell lung cancer, breast cancer, bladder cancer and melanoma. Researchers plan to integrate single cell and spatial biology with clinical outcomes data to better understand mechanisms of response and resistance across a range of therapeutic approaches, including antibody-drug conjugates, bispecific antibodies and immune checkpoint inhibitors. The collaboration also intends to investigate how 10x single cell and spatial technologies can be deployed clinically alongside current standard-of-care assays.

“The promise of precision oncology depends on understanding the biology that helps determine which therapies are most likely to benefit a given patient,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “We believe single cell and spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment, creating opportunities to discover biomarkers that can help guide treatment decisions and enable future diagnostic approaches in cancer care.”

The collaboration is expected to generate a comprehensive, multimodal resource integrating single cell and spatial data to enable the discovery of clinically actionable biomarkers of treatment response and resistance. It also plans to evaluate how these biomarkers could be incorporated into future clinical reporting frameworks to support personalized treatment planning and molecular tumor board decision-making.